Bioxcel Therapeutics Equity-NMS: BTAI

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$0.4099

Open :

$0.4

Today's high :

$0.42

Today's low :

$0.4

52W low :

$0.3553

52W high :

$4.17

EPS(TTM): :

-1.94

Shares O/S :

48.35 M

Market cap :

21.27 M

What is the share price of Bioxcel Therapeutics today?

Bioxcel Therapeutics (BTAI) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Bioxcel Therapeutics?

Yes, Indian Investors can invest in the Bioxcel Therapeutics (BTAI) Share by opening an international trading account with Angel One.

How can I purchase Bioxcel Therapeutics shares in India?

Purchasing Bioxcel Therapeutics (BTAI) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Bioxcel Therapeutics (BTAI) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Bioxcel Therapeutics?

Yes, you can purchase fractional shares of Bioxcel Therapeutics (BTAI) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Bioxcel Therapeutics?

The market capitalization of Bioxcel Therapeutics on January 1, 1970, is $0.

What documents are required to invest in Bioxcel Therapeutics stocks?

In order to invest in Bioxcel Therapeutics (BTAI) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.